Saccharomyces boulardii ： Clostridioides difficile Infection (CDI)
BMeta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dclostridioides\u002Ddifficile';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.
Key Study Findings
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: Pediatric population
Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None
vs: None
Outcome: C. difficile infection treatment outcomes
効果: None
None
対象集団: Patients with C. difficile infection
Review
520 weeks
Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: None
Review
Clostridium difficile Colitis Prevention and Treatment.
Dose: None
vs: None
Outcome: Diarrhea outcomes
効果: None
None
対象集団: None
Systematic Review
n=228
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.
Dose: None
vs: None
Outcome: Diarrhea outcomes
効果: None
None
対象集団: None
Review
Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?
Dose: None
vs: None
Outcome: GI condition outcomes (C. diff, AAD, H. pylori)
効果: None
None
対象集団: Adults with GI conditions
Key Statistics
6
研究数
3000
参加者数
↑
Positive
B
グレード
Referenced Papers
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 件の引用
Advances in experimental …
2024
2 件の引用
Cureus
2023
5 件の引用
Advances in experimental …
2019
17 件の引用
Frontiers in medicine
2018
450 件の引用
Pharmacological research
2018
132 件の引用
The American journal …
2018
46 件の引用
World journal of …
2017
68 件の引用
Journal of pediatric …
2016
233 件の引用
Clinical and experimental …
2016
82 件の引用
Open forum infectious …
2016
58 件の引用
Antibiotics (Basel, Switzerland)
2015
104 件の引用
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 件の引用
The American journal …
2012
104 件の引用
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use.
Other
The American journal …
2012
5 件の引用
Journal of clinical …
2011
432 件の引用
Probiotics.
Review
American journal of …
2010
Current opinion in …
2009
82 件の引用
The American journal …
2006
918 件の引用
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 件の引用
Medical science monitor …
2006
The American journal …
2001
648 件の引用
International journal of …
2000
181 件の引用
Clinical infectious diseases …
1998
346 件の引用
Anaerobe
1997
40 件の引用
Gastroenterology
1989
418 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 250-500 mg/day (equivalent to 5-10 billion CFU)
- aadprevention:
- 500 mg/day (start with antibiotic, continue 7 days after)
- cdiffprevention:
- 500 mg twice daily as adjunct to standard therapy
- travelersdiarrhea:
- 250-500 mg/day starting 5 days before travel
上限量： Well-tolerated up to 1,000 mg/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | 520 weeks | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | 228 |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
推奨摂取タイミング： Can be taken with or without food; space 2 hours from antifungals
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas and bloating
- ⚠ Rare: fungemia in critically ill patients with central venous catheters
- ⚠ Thirst (yeast may increase water requirements)
- ⚠ Very rare: potential environmental contamination risk in ICU settings
既知の相互作用
- ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
- ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
- ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)
耐容上限摂取量： Well-tolerated up to 1,000 mg/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Saccharomyces boulardii help with Clostridioides difficile Infection (CDI)?
Based on 6 studies with 3,000 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support Clostridioides difficile Infection (CDI) management. Our evidence grade is B (Good Evidence).
How much Saccharomyces boulardii should I take for Clostridioides difficile Infection (CDI)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Clostridioides difficile Infection (CDI)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 6 peer-reviewed studies with 3,000 total participants. The overall direction of effect is positive.
Related Evidence
Saccharomyces boulardii 他の症状・状態について
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。